New insights on the use of desipramine as an inhibitor for acid ceramidase.
about
Identification of novel functional inhibitors of acid sphingomyelinaseHsp70.1 and related lysosomal factors for necrotic neuronal deathTamoxifen regulation of sphingolipid metabolism--Therapeutic implicationsMultiple cationic amphiphiles induce a Niemann-Pick C phenotype and inhibit Ebola virus entry and infectionDynamics of ceramide generation and metabolism in response to fenretinide--Diversity within and among leukemiaAdjustment of Dysregulated Ceramide Metabolism in a Murine Model of Sepsis-Induced Cardiac Dysfunction.Inhibition of SREBP1 sensitizes cells to death ligands.Oxidative stress and autophagy in the regulation of lysosome-dependent neuron death.Regulation of CC ligand 5/RANTES by acid sphingomyelinase and acid ceramidase.C6-ceramide synergistically potentiates the anti-tumor effects of histone deacetylase inhibitors via AKT dephosphorylation and α-tubulin hyperacetylation both in vitro and in vivo.The contribution of lysosomotropism to autophagy perturbation.Acid ceramidase expression modulates the sensitivity of A375 melanoma cells to dacarbazine.Ceramide--antiestrogen nanoliposomal combinations--novel impact of hormonal therapy in hormone-insensitive breast cancer.Adventures within the speckled band: heterogeneity, angiogenesis, and balanced inflammation in the tuberculous granuloma.Anti-ceramidase LCL385 acutely reduces BCL-2 expression in the hippocampus but is not associated with an increase of learned helplessness in rats.Ceramide in bacterial infections and cystic fibrosis.Roles and regulation of secretory and lysosomal acid sphingomyelinase.Selective inhibition of Ebola entry with selective estrogen receptor modulators by disrupting the endolysosomal calcium.Endogenous ceramide contributes to the transcytosis of oxLDL across endothelial cells and promotes its subendothelial retention in vascular wall.Biological function of the cellular lipid BMP-BMP as a key activator for cholesterol sorting and membrane digestion.Drug targeting of sphingolipid metabolism: sphingomyelinases and ceramidases.Host-Directed Therapies for Tuberculosis.Gilenya (FTY720) inhibits acid sphingomyelinase by a mechanism similar to tricyclic antidepressants.Autophagy is increased in prostate cancer cells overexpressing acid ceramidase and enhances resistance to C6 ceramide.Acid sphingomyelinase promotes endothelial stress response in systemic inflammation and sepsis.Potent inhibition of Acid ceramidase by novel B-13 analogues.TNF dually mediates resistance and susceptibility to mycobacteria via mitochondrial reactive oxygen species.Tricyclic Antidepressants Promote Ceramide Accumulation to Regulate Collagen Production in Human Hepatic Stellate Cells.Sphingosine 1-phosphate activation of ERM contributes to vascular calcification.Structural basis for the activation of acid ceramidase.
P2860
Q21003953-A4CCA37A-04F1-4979-A691-9A9E78C09A43Q27012978-F8556434-E047-4551-A41F-EFD3EF8DAC0DQ28084270-E2553DF8-32CB-411E-887C-A7D9FC7663B2Q28486226-CFFEA588-3D1E-44C3-8D61-51D549B3A5E3Q30278944-416FB476-6ECF-404C-9F9E-D37D86CBC9E0Q33624807-A6EF83F3-7AFF-40DA-B415-91A0C0507709Q33846866-DBAFD91C-3E80-4245-9726-58FF3BDE7B6EQ34104922-13E057DC-E47F-4F3D-954B-4879EB7CC54BQ34787157-4187AB09-99CA-4B01-8F09-5750CDC2EA56Q34797621-7DBAA17E-82E5-420F-B127-94B0709B3FA7Q35054164-B8F2CE6F-3D23-46D6-8771-76A46C59E0A6Q35150141-FC88A790-605D-4EEB-A810-7363B264FFE8Q36392653-78DD6025-823F-4FFF-94EC-21B1EA45827EQ36439790-D0435C90-C1E7-4266-9308-3AE568E23FD9Q37086344-9F019B00-51A9-4D9E-899D-0BD89E40D5D4Q37265533-0CC39642-B535-4A58-8364-0EC623297C50Q37454661-B19766D8-3604-4930-9040-D36C06602AD7Q37602125-AA9EB0A4-8F09-49B8-986D-E52594C4C50CQ37730677-FAEEEEDC-94AF-4A01-B9D4-3C4FC4804E03Q37817029-B78FF501-1748-42DD-B982-AC1A3209DF5FQ37880161-004B06E6-DA7B-4AE5-AC10-1F50BC9899C4Q38489473-FFBF6D51-4568-48D4-AADA-8D5CBA6433C0Q39624007-125876BE-1AC1-46D0-99D1-95709FA198CBQ39626125-7E41AC3A-EEE2-4736-8F46-B4509D499459Q40637739-87821005-AD71-4F2D-9F58-00C3FCE7A622Q41785136-62CA042E-A01C-4566-A8E0-0832E34D9593Q41816750-558ACBDF-CCB0-4829-B3BB-2764321B6993Q42315013-B2822716-BD52-4E4C-B48D-64EA88C1B686Q46273824-C22835F5-3937-4048-A725-D5CC7BFDB226Q55248134-897D09D1-0B38-45F2-AC02-5C115966AE1D
P2860
New insights on the use of desipramine as an inhibitor for acid ceramidase.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
New insights on the use of desipramine as an inhibitor for acid ceramidase.
@en
type
label
New insights on the use of desipramine as an inhibitor for acid ceramidase.
@en
prefLabel
New insights on the use of desipramine as an inhibitor for acid ceramidase.
@en
P2093
P2860
P1433
P1476
New insights on the use of desipramine as an inhibitor for acid ceramidase.
@en
P2093
Ahmed El-Zawahry
Alicja Bielwaska
Ayman Mahdy
David H Holman
James S Norris
Joseph C Cheng
Maristella Villani
Saeed Elojeimy
Youssef Zeidan
P2860
P304
P356
10.1016/J.FEBSLET.2006.07.071
P407
P577
2006-08-04T00:00:00Z